Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (PERSIST): A multicenter phase II trial

Feilin Cao, Zhaosheng Ma, Zenggui Wu, Weizhu Wu, Ouchen Wang, Binbin Cui, Xiaotao Zhu, Jing Hao, Xiaochun Ji, Zhanwen Li, Deyou Tao, Qingjing Feng, Wei Lin, Dongbo Shi, Jingde Shu, Jichun Zhou, Shifen Huang
doi: https://doi.org/10.1101/2024.09.05.24313095

Data availability statement

Data supporting the findings of this study are available from the corresponding author upon reasonable request.

Back to top
Posted December 27, 2024.
Download PDF
Data/Code
Email
Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (PERSIST): A multicenter phase II trial
Feilin Cao, Zhaosheng Ma, Zenggui Wu, Weizhu Wu, Ouchen Wang, Binbin Cui, Xiaotao Zhu, Jing Hao, Xiaochun Ji, Zhanwen Li, Deyou Tao, Qingjing Feng, Wei Lin, Dongbo Shi, Jingde Shu, Jichun Zhou, Shifen Huang
medRxiv 2024.09.05.24313095; doi: https://doi.org/10.1101/2024.09.05.24313095
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area